Summary
It has been demonstrated that hairy cell leukemia (HCL) can be efficiently treated by various preparations of alpha interferons (IFN). Nevertheless, there are several open questions, such as the route, mode and dosage of IFN application. These variables of IFN treatment may be critical since a myelosuppressive effect of IFN, which is commonly seen in the initial phase of treatment, can result in further deterioration of the already impaired platelet production in advanced HCL. The present study shows that serious side effects can be avoided and the flulike syndromes described by others almost completely reduced by s.c. application of IFN via a portable pump during a daily 8 h period. IFN is initially given five times a week and the daily dose is adjusted according to the actual platelet count. The efficiency controls show that the increase of platelets in the peripheral blood, which is most critical in advanced HCL, may be seen earlier by this than by other protocols, which usually recommend higher daily doses of IFN and only three instead of five weekly applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Catovsky D, O'Brien M, Melo JV, Wardle J, Brozovic M (1984) Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolylmphocytic leukemia. Semin Oncol 11: 362–369
Dührsen U, Mensers P, Gries E, Brittinger G (1984) Interferon Therapie bei HCL: Ein neuer therapeutischer Ansatz. Blut 49: 282
Flandrin G, Sigaux F, Sebahovn G and Bouffette P (1984) Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 11: 458–471
Foon KA, Maluish AE, Abrams PG, Wrightingzon S, Schnipper EF, Herbermann RB (1984) A phase II trial of rec leukocyte A IFN for advanced HCL: therapeutic and immunological results. Blood 64: 567
Gastl G, Denz H, Abbrederis C, Huber H, Troppmair J, Wiegele J, Niederwieser D, Flener R, Huber C (1985) Treatment with low dose human recombinant interferon alpha 2 arg induces complete remission in patient with HCL. Onkologie, in press
Golomb HM, Ratain M, Vokes E, Jacobs R, Verdiman J, Daly K (1984) Treatment of advanced HCL with rec alpha 2 interferon. 2nd International Conference on Malignant Lymphoma, Lugano
Golth D, Schwarzmeier J, Prischl F, Haas O, Georgopoulous A, Miksche M, Taschner H (1984) Partial remission of HCL after treatment with alpha 2 rec IFN. Blut 49: 282–283
Hofmann V, Scheel A, Fehr J, Dubas JC, Grasselli G, Kaplan S, Sauter C (1984) Treatment of HCL with IFN alpha 2 (E. coli). 2nd International Conference on Malignant Lymphoma, Lugano
Jacobs AD, Champlin RE, Golde DW (1984) Response of patients with HCL to biosynthetic (rec) alpha IFN. Blood 64: 573
Jansen J, den Ottolander GJ, Holdrinet RSG, Tricot GJK, Hermans J (1984) Prognosis and therapy in hairy cell leukemia. Semin Oncol 11: 472–478
Janssen JTP, de Pauw BE, Holdrinet RSG (1984) Treatment of HCL with rec human alpha 2 IFN. Lancet I: 1025–1026
Leavitt RD, Kaplan RS, Ferraresi R, Meredeth G, Rudnick S (1984) High and low dose alpha 2 IFN treatment for high and low grade NHL. 2nd International Conference on Malignant Lymphoma, Lugano
Mahmoud HK, Öhl S, Schaefer UW, Beelen D, Grosse-Wilde H, Doxiadis I, Richter HJ, Schmidt CG (1985) Treatment of HCL with recombinant leukocyte A IFN. Onkologie, in press
Mogensen KE, Cantell K (1977) Production and preparation of human leukocyte interferon. Pharm Ther C 1: 369
Quesada JR, Reuben J, Mannige JT, Hersh EM, Gutterman JU (1984) Alpha-interferon for induction of remission in HCL. N Engl J Med 310: 15–18
Quesada JR, Hersh EM, Gutterman JU (1984) Treatment of HCL with alpha-interferon. Proc Am Soc Clin Oncol 2nd annual meeting, Toronto
Quesada JR, Hersh EM, Gutterman JU (1984) Therapy of HCL with interferon alpha. Antiviral Res Abstract issue, TNO/ISIR Congress, Heidelberg
Ratain M, Jacobs R, Vokes E, Vardiman J, Golomb HM (1984) A phase II trial of rec alpha IFN in advanced HCL. XX Congr Int Soc Hematol, Buenos Aires, Argentina
Ratain M, Golomb HM, Vardiman JW, Bardawil R, Daly K (1984) Effective treatment of HCL with rec alpha 2 IFN in 20 patients. Blood 64: 599
Spiegel R (1985) Clinical application of IFN alpha 2. A review of early studies. E.O.R.T.C. Symposium on Interferon alpha 2 in Cancer Therapy, Brussels
Thompson JA, Fefer A, Bonnem E (1984) The treatment of HCL with rec alpha 2 IFN. Blood 64: 615
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Porzsolt, F., Thomä, J., Unsöld, M. et al. Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut 51, 73–82 (1985). https://doi.org/10.1007/BF00320115
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320115